Soleno Therapeutics Inc Market Cap ($2.76 Billion)
Market Cap & Net Worth: Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc market cap. Soleno Therapeutics Inc (NASDAQ:SLNO) has a market capitalization of $2.76 Billion ($2.76 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5008 globally and #1708 in its home market, demonstrating a 0.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Soleno Therapeutics Inc's stock price $53.01 by its total outstanding shares 52120147 (52.12 Million). Also see SLNO operating cash flow for how efficiently the company converts equity into cash flow.
Soleno Therapeutics Inc Market Cap History (2015–2026)
Soleno Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $7.23 Billion to $2.76 Billion (-10.32% CAGR). Check current stock price of Soleno Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Soleno Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.11% | #134 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.01% | #572 of 3165 |
Weight: Soleno Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Soleno Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Soleno Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Soleno Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
12.67x
Soleno Therapeutics Inc's market cap is 12.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
115.52x
Soleno Therapeutics Inc's market cap is 115.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.17 Billion | $1.45 Million | -$12.07 Million | 2182.47x | N/A |
| 2017 | $1.41 Billion | $-1.55 Billion | -$15.67 Million | -0.91x | N/A |
| 2025 | $2.41 Billion | $190.41 Million | $20.89 Million | 12.67x | 115.52x |
Competitor Companies of SLNO by Market Capitalization
Companies near Soleno Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Soleno Therapeutics Inc for a full breakdown of the balance sheet.
Key companies related to Soleno Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Soleno Therapeutics Inc (2015–2026)
Market capitalization of Soleno Therapeutics Inc from 2015 to today. Between 2015 and today, Soleno Therapeutics Inc's market cap moved from $7.23 Billion to $ 2.76 Billion, with a yearly change of -10.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.76 Billion | +14.49% |
| 2025 | $2.41 Billion | +3.00% |
| 2024 | $2.34 Billion | +11.68% |
| 2023 | $2.10 Billion | +1932.83% |
| 2022 | $103.20 Million | -67.80% |
| 2021 | $320.54 Million | -78.76% |
| 2020 | $1.51 Billion | -34.35% |
| 2019 | $2.30 Billion | +71.93% |
| 2018 | $1.34 Billion | -5.00% |
| 2017 | $1.41 Billion | -55.56% |
| 2016 | $3.17 Billion | -56.22% |
| 2015 | $7.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Soleno Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.76 Billion USD |
| MoneyControl | $2.76 Billion USD |
| MarketWatch | $2.76 Billion USD |
| marketcap.company | $2.76 Billion USD |
| Reuters | $2.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more